Research Progress of Long Non-Coding RNA in Hematological Tumors --Review.
10.19746/j.cnki.issn.1009-2137.2023.01.049
- Author:
Feng LI
1
;
Fei-Fei YANG
2
;
Yan-Li XU
3
Author Information
1. Department of Hematology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, Jiangsu Province, China.
2. Department of Hematology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, Jiangsu Province, China,E-mail:lydia9017@sina.com.
3. Department of Hematology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, Jiangsu Province, China,E-mail: xuyanli62@sohu.com.
- Publication Type:Journal Article
- Keywords:
biomarker;
hematologic malignancies;
long non-coding RNA;
therapeutic target
- MeSH:
Humans;
RNA, Long Noncoding/metabolism*;
Hematologic Neoplasms/genetics*;
Neoplasms;
Carcinogenesis/pathology*;
Cell Transformation, Neoplastic/genetics*;
Gene Expression Regulation, Neoplastic
- From:
Journal of Experimental Hematology
2023;31(1):306-310
- CountryChina
- Language:Chinese
-
Abstract:
Long non-coding RNA (lncRNA) is a hot topic in the field of researching tumor pathogenesis, and the importance in hematologic malignancies has been gradually being elucidated. LncRNA not only regulates hematological tumorigenesis and progression through affecting various biological processes such as cell proliferation, differentiation, pluripotency and apoptosis; moreover, abnormal expression and mutation of lncRNA are closely related to drug resistance and prognosis. Thus lncRNA can be used as novel biomarker and potential therapeutic target for hematological tumors. In this review, we will focus on the latest progress of lncRNA in hematological tumors to provide new ideas for the clinical diagnosis, prognostic evaluation together with research and development of target drugs for hematologic malignancies.
